MAYO CLINIC
Mayo Medical Laboratories

# Laboratory Service Report 1-800-533-1710

| Patient Name | Patient ID | Age | Gender | Order # |
|---|---|---|---|---|
| TESTINGRNV,BRAFMREPORT | SA00047822 | 56 | M | SA00047822 |

| Ordering Phys | | DOB |
|---|---|---|
| | | 08/08/1955 |

| Client Order # | Account Information | Report Notes |
|---|---|---|
| SA00047822 | C7028846-DLMP ROCHESTER<br>3050 SUPERIOR DRIVE<br>ROCHESTER,MN 55901 | |
| **Collected**<br>07/18/2012 | | |
| **Printed**<br>08/02/2012 14:40 | | |

| Test | Flag | Results | Unit | Reference Value | Perform Site* |
|---|---|---|---|---|---|
| **BRAF Mutation AnalysisV600 Melanoma** | | REPORTED 07/18/2012 16:31 | | | |
| Specimen | | Tissue-Tumor | | | MCR |
| Specimen ID | | 1038400 | | | MCR |
| Order Date | | 18 Jul 2012 11:15 | | | MCR |
| Reason for Referral | | | | | MCR |
| Evaluate tumor tissue for the presence of the V600 mutation in the BRAF gene. | | | | | |
| Method | | | | | MCR |
| A PCR based assay is used to test tumor DNA for the presence of a V600 (Val600) mutation within the BRAF gene. | | | | | |
| Result | | | | | MCR |
| Tumor type: metastatic melanoma<br>A BRAF V600 mutation was detected. | | | | | |
| Interpretation | | | | | MCR |

Current data suggests that the efficacy of BRAF targeted therapy in melanoma is limited to patients whose tumors contain a V600 mutation. Thus, the presence of a V600 mutation in this tumor specimen suggests that this patient may respond to such therapy.

Please note, not all patients with a BRAF mutation will respond to anti BRAF therapies. This result does not rule out the presence of a mutation that may be present but below the limit of detection for this assay (approximately 10%).

Of note, although a BRAF V600 mutation is commonly present early in melanoma development, discordant results between primary and metastatic lesions can occur.

Consideration of these results in light of other clinical information, such as previous chemotherapeutic treatments including anti-BRAF therapy, may aid in the clinical management decisions for this patient.

CAUTIONS:
Not all patients that have BRAF mutations respond to BRAF-targeted therapies.

Rare polymorphisms exist that could lead to false-negative or false-positive results.

Test results should be interpreted in context of clinical findings, tumor sampling, and other laboratory data. If

***Performing Site Legend on Last Page of Report***



* Report times for Mayo performed tests are CST/CDT

| Patient Name | Patient ID | Age | Gender | Order # |
|---|---|---|---|---|
| TESTINGRNV,BRAFMREPORT | SA00047822 | 56 | M | SA00047822 |
| **Ordering Phys** | | | | **DOB** 08/08/1955 |
| **Client Order #** SA00047822 | **Account Information** | | | **Report Notes** |
| **Collected** 07/18/2012 | C7028846-DLMP ROCHESTER<br>3050 SUPERIOR DRIVE<br>ROCHESTER,MN 55901 | | | |
| **Printed** 08/02/2012 14:40 | | | | |

| Test | Flag | Results | Unit | Reference Value | Perform Site* |
|---|---|---|---|---|---|
| results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete. | | | | | |
| This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements. | | | | | |
| Review By | | | | | MCR |
| Emily Christine Lauer | | | | | |
| Release Date | | 18 Jul 2012 16:29 | | | MCR |

* Performing Site:

| | | |
|---|---|---|
| MCR | Mayo Clinic Laboratories - Rochester Main Campus<br>200 First St SW Rochester, MN 55905 | Lab Director: |